ClinicalTrials.Veeva

Menu

Clinical-pathological Characterization and Outcomes of Metastatic Urothelial Cancer in Latin America

L

Latin American Cooperative Oncology Group (LACOG)

Status

Completed

Conditions

Recurrent/Metastatic Urothelial Cancers

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT03942497
LACOG 1518

Details and patient eligibility

About

The LACOG 1518 study will characterize demographic and clinical-pathological profile of patients diagnosed with recurrent/ metastatic urothelial cancer in Latin America.

Enrollment

218 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Age at least 18 years;
  2. Histological confirmation of urothelial carcinoma (include mixed urothelial histology);
  3. Diagnosis of recurrent or metastatic (Stage IV) urothelial carcinoma during the period of January 2016 to July 2018;
  4. Site and investigator ability to collect adequate patient characteristics, treatment and outcome data from medical records;
  5. Availability of tumor sample (FFPE/slides) from primary tumor or metastatic site at the time of registration.

Exclusion criteria

  1. Synchronous tumors or history of other malignancy in the previous 3 years before study entry (exception to non-melanoma skin cancer or non-invasive cancers);
  2. Pure non-urothelial carcinoma histology.

Trial contacts and locations

9

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems